Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb;24(1):e50-e54.
doi: 10.3747/co.24.3182. Epub 2017 Feb 27.

Examining the medical resource utilization and costs of relapsed and refractory chronic lymphocytic leukemia in Ontario

S Hassan  1 , S J Seung  1 , M C Cheung  2 , G Fraser  3 , B Kuriakose  4 , C Trambitas  4 , N Mittmann  5
Affiliations

Examining the medical resource utilization and costs of relapsed and refractory chronic lymphocytic leukemia in Ontario

S Hassan et al. Curr Oncol. 2017 Feb.

Abstract

Purpose: The purpose of the present study was to collect medical resource utilization data and costs in Ontario for the management of patients with relapsed or refractory chronic lymphocytic lymphoma (cll) who have undergone at least 1 treatment course and have been stratified by Rai staging.

Methods: This retrospective longitudinal cohort study, conducted by chart review, analyzed anonymized patient records from two cancer centres in Ontario. Comprehensive records of 86 patients meeting the inclusion criteria were used to obtain resource utilization, which, multiplied by unit costs, were used to determine overall and mean costs. Descriptive statistics are presented for patient demographics, medical resource utilization, and costing data.

Results: The total cost for the cohort was $2.2 million over a mean follow-up period of 4.7 years. The mean total cost per patient (regardless of follow-up) was $25,736. In terms of Rai staging, overall mean costs were highest for stage iv patients. Almost 50% of the total cost was attributable to cll treatments, among which fludarabine-based treatments had the highest utilization.

Conclusions: For this Canadian cll cohort, medical resource utilization and costs were determined to be $2.2 million, with cll treatments accounting for about half the cost. Costs generally increased with Rai stage.

Keywords: Canada; Chronic lymphocytic leukemia; costs; utilization.

PubMed Disclaimer

References

    1. United States, Department of Health and Human Services, National Institutes of Health, National Cancer Institute (nci) Chronic lymphocytic leukemia treatment (PDQ)—patient version [Web page] Bethesda, MD: NCI; 2016. [Available at: http://www.cancer.gov/types/leukemia/patient/cll-treatment-pdq; cited 28 July 2016]
    1. Carney DA, Mulligan SP. Chronic lymphocytic leukaemia: current first-line therapy. Intern Med J. 2009;39:44–8. doi: 10.1111/j.1445-5994.2008.01863.x. - DOI - PubMed
    1. Seftel MD, Demers AA, Banerji V, et al. High incidence of chronic lymphocytic leukemia (cll) diagnosed by immunophenotyping: a population-based Canadian cohort. Leuk Res. 2009;33:1463–8. doi: 10.1016/j.leukres.2009.06.013. - DOI - PubMed
    1. Canadian Cancer Society . Chronic lymphocytic leukemia statistics [Web page] Toronto, ON: Canadian Cancer Society; n.d. [Available at: http://www.cancer.ca/en/cancer-information/cancer-type/leukemia-chronic-...; cited 29 November 2016]
    1. Canadian Cancer Society . Risk factors for chronic lymphocytic leukemia [Web page] Toronto, ON: Canadian Cancer Society; n.d. [Available at: http://www.cancer.ca/en/cancer-information/cancer-type/leukemia-chronic-...; cited 28 July 2016]

LinkOut - more resources